AWM
ALNY icon

Apollon Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Apollon Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$334K Buy
1,109
+342
+45% +$103K ﹤0.01% 1208
2026
Q1 		$254K Buy
+767
New +$261K ﹤0.01% 1196

Other funds holding ALNY

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
SSA
Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return
FISPB
Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return

Apollon Wealth Management's ALNY Position: Q2 2026 in Review

Apollon Wealth Management increased its Alnylam Pharmaceuticals (ALNY) stake by 45% in Q2 2026, buying an estimated $103K and bringing the position to 1,109 shares worth $334K. The position accounts for ﹤0.01% of the portfolio, ranked #1208.

Apollon Wealth Management first reported a position in ALNY in Q1 2026 and has held it in 2 quarters since. 149 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Apollon Wealth Management held 1,109 shares of Alnylam Pharmaceuticals worth $334K as of Q2 2026.
  • Apollon Wealth Management bought 342 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $103K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Apollon Wealth Management's portfolio in Q2 2026, its #1208 holding.
  • Apollon Wealth Management first reported a position in Alnylam Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 149 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Apollon Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.